Working… Menu

A Study of BPI-1178 in Patients With Advanced Solid Tumor and HR+/HER2- Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04282031
Recruitment Status : Recruiting
First Posted : February 24, 2020
Last Update Posted : July 30, 2021
Information provided by (Responsible Party):
Beta Pharma (Suzhou) Co., Ltd.

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : June 30, 2023
Estimated Study Completion Date : March 15, 2024